drugset / Trial / NCT02238717

Assessment of the Analgesic Effects of PF-06372865 in Healthy Volunteers Using Evoked Pain Endpoints

NCT02238717

Phase 1 Completed 20 enrolled Pfizer
RandomizedCrossoverDouble-blindBasic science

Summary

This study will examine the activity of 2 different doses of PF-06372865 on a panel of evoked pain tests carried out from 0.5 to 10 hours following oral dosing in healthy male subjects.

Timeline

Start
2014-09
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Darigabat Small molecule 15 mg Oral
Subject Darigabat Small molecule 65 mg Oral
Comparator Pregabalin Small molecule 300 mg Oral

Indications

No indication recorded.